University Hospital, Toulouse
chu-toulouse.frTotal trials
786
Active
190
Phase 3
36
Total enrollment
1,102,462
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 57 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Stopping dupilumab | — | — | — | — | — | 1 | |
| Baricitinib (LY3009104) 4 mg | — | — | — | — | — | 1 | |
| filgotinib 200mg/day | — | — | — | — | — | 1 | |
| Tofacitinib 5 mg twice daily | — | — | — | — | — | 1 | |
| Upadacitinib 15 MG | — | — | — | — | — | 1 | |
| a second infusion of ZOL when crosslaps levels reach 300 pg/mL | — | — | — | — | — | 1 | |
| a rescue second infusion at month-12 | — | — | — | — | — | 1 | |
| Aspirin | — | — | — | — | 2 | ||
| Carboplatin | — | — | — | — | — | 1 | |
| Paclitaxel | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Propranolol Oral Product | — | — | — | — | — | 1 | |
| Avacopan | — | — | — | — | — | 1 | |
| 1 hour | — | — | — | — | — | 1 | |
| 4 hours | — | — | — | — | — | 1 | |
| ultrasound-guided betamethasone infiltration of the meniscal wall | — | — | — | — | — | 1 | |
| ultrasound-guided isotonic saline (placebo) infiltration of the meniscal wall | — | — | — | — | — | 1 | |
| BOTOX | — | — | — | — | — | 1 | |
| Amoxi Clavulanate | — | — | — | — | — | 1 | |
| AdMSC | — | — | — | — | — | 3 | |
| Oxytocin nasal spray | — | — | — | — | 2 | ||
| rapamycin | — | — | — | — | — | 2 | |
| Milrinone | — | — | — | — | — | 1 | |
| TEP with 18F-DPA-714 | — | — | — | — | — | 1 | |
| CellREADY® drug product IV dose of 50 millions | — | — | — | — | — | 1 | |
| CellREADY® drug product IV dose of 100 millions | — | — | — | — | — | 1 | |
| a positon emission tomography (PET) exam | — | — | — | — | — | 1 | |
| Gentamicin Injectable Solution | — | — | — | — | — | 1 | |
| Amantadine (100mg) as add on therapy. | — | — | — | — | — | 1 | |
| IV Ketamine (0.5 mg/kg) Infusion - Two Doses Administered 24 Hours Apart for Severe Borderline Personality Disorder | — | — | — | — | — | 1 | |
| Adipose tissue derived mesenchymal Stroma/stem Cells transplantation | — | — | — | — | — | 1 | |
| Acyclovir | — | — | — | — | — | 1 | |
| Blood sampling | — | — | — | — | — | 6 | |
| Blood samples | — | — | — | — | — | 3 | |
| Blood collection on admission and longitudinally | — | — | — | — | — | 3 | |
| Collection of blood and urine | — | — | — | — | — | 2 | |
| Azacitidine | — | — | — | — | 2 | ||
| Biological samples collection | — | — | — | — | — | 1 | |
| Blood and bone marrow sampling | — | — | — | — | — | 1 | |
| semen, blood and urine tests | — | — | — | — | — | 1 |
17 more active programs hidden
Next readouts
- 2025-02
- 2025-05-01
- 2025-07
- 2025-09
- 2026-02
- 2026-02
- 2026-04-01
- 2026-04-20
- 2026-06-08
- 2026-07-07
Top conditions
- Parkinson Disease23
- Obesity16
- Prader-Willi Syndrome15
- Multiple Myeloma12
- Stroke12
- Alzheimer Disease11
- Pain8
- COVID-198
Frequently asked questions about University Hospital, Toulouse
- How many clinical trials does University Hospital, Toulouse have on ClinicalTrials.gov?
- University Hospital, Toulouse is listed as the lead sponsor on 786 clinical trials in ClinicalTrials.gov, 190 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Toulouse's trials are in Phase 3?
- 36 of University Hospital, Toulouse's trials are in Phase 3, spread across 57 active drug programs.
- What therapeutic areas does University Hospital, Toulouse focus on?
- University Hospital, Toulouse's most-studied conditions on ClinicalTrials.gov are Parkinson Disease, Obesity, Prader-Willi Syndrome, Multiple Myeloma, Stroke.
- When are University Hospital, Toulouse's next clinical trial readouts?
- University Hospital, Toulouse has 10 upcoming primary-completion readouts tracked here; the soonest is “Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia”, expected around 2025-02.